Rice Hall James & Associates LLC Has $16.23 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Rice Hall James & Associates LLC raised its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 8.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 649,630 shares of the company's stock after buying an additional 49,000 shares during the period. Kiniksa Pharmaceuticals comprises 0.9% of Rice Hall James & Associates LLC's investment portfolio, making the stock its 29th largest position. Rice Hall James & Associates LLC owned 0.92% of Kiniksa Pharmaceuticals worth $16,234,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in KNSA. Acadian Asset Management LLC boosted its stake in Kiniksa Pharmaceuticals by 167.8% during the 1st quarter. Acadian Asset Management LLC now owns 164,568 shares of the company's stock valued at $3,240,000 after acquiring an additional 103,120 shares during the last quarter. Sei Investments Co. acquired a new position in Kiniksa Pharmaceuticals during the first quarter worth about $1,450,000. Dimensional Fund Advisors LP grew its stake in shares of Kiniksa Pharmaceuticals by 31.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company's stock worth $12,398,000 after purchasing an additional 157,741 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 8.1% in the first quarter. SG Americas Securities LLC now owns 19,160 shares of the company's stock valued at $378,000 after buying an additional 1,435 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Kiniksa Pharmaceuticals by 159.8% during the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company's stock valued at $11,612,000 after acquiring an additional 382,539 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA traded down $0.11 during midday trading on Friday, hitting $22.48. The stock had a trading volume of 358,298 shares, compared to its average volume of 412,544. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -160.52 and a beta of 0.33. The company has a 50 day simple moving average of $25.40 and a two-hundred day simple moving average of $22.46. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $14.12 and a twelve month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The business had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business's revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.20) EPS. Analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.38 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 17,000 shares of the company's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the transaction, the chief operating officer now owns 109,975 shares of the company's stock, valued at approximately $2,955,028.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares in the company, valued at $1,359,232.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eben Tessari sold 17,000 shares of the business's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the sale, the chief operating officer now directly owns 109,975 shares of the company's stock, valued at $2,955,028.25. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 112,692 shares of company stock worth $2,950,315. 54.57% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KNSA. Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a "buy" rating and a $40.00 price target on the stock. Wedbush increased their price target on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an "outperform" rating in a report on Tuesday, July 23rd. Finally, Evercore ISI upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $34.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.